Searchable abstracts of presentations at key conferences in endocrinology

ea0081rc8.3 | Rapid Communications 8: Calcium and Bone | ECE2022

What is the most efficient way to fortify food items with vitamin D? A randomised, multiple crossover study

Espersen Rasmus , Ring Madsen Lene , Nebel Caroline , Danielsen Marianne , Dalsgaard Trine , Rejnmark Lars

Introduction: Vitamin D insufficiency (25-hydroxy vitamin D <50 nmol/l) is a global health problem. Vitamin D food fortification might be the solution, but knowledge is sparse on whether fortification of various food items affects the bioavailability differently. It is generally assumed that ingesting vitamin D with a fatty meal improves the bioavailability of vitamin D. Furthermore, complex formation with whey protein isolate (WPI) may enhance the stability of vitamin D a...

ea0032p875 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Thirty-day mortality in acute non-surgical patients admitted with hyponatremia

Holland-Bill Louise , Christiansen Christian , Ring Troels , Toft Sorensen Henrik , Lunde Jorgensen Jens Otto

Introduction: Hyponatremia (serum sodium ≤135 mmol/l), the most common electrolyte disorder encountered, has been associated with increased mortality in patients with particularly cancer, heart failure, chronic kidney and liver disease. However, evidence of the clinical implications in broader populations is scarce, and uncertain due to confounding from preexisting disease. We aimed to examine the association between admission-hyponatremia and 30-day mortality in acute n...

ea0029p708 | Diabetes | ICEECE2012

The Sodium Glucose Cotransporter-2 Inhibitor Empagliflozin Does Not Alter ECG Endpoints in a Thorough QT (TQT) Study

Ring A. , Brand T. , Macha S. , Breithaupt-Groegler K. , Simons G. , Walter B. , Woerle H. , Broedl U.

Empagliflozin is a potent, highly selective sodium glucose cotransporter-2 inhibitor in development for treatment of type 2 diabetes mellitus. This randomized, placebo-controlled, double-blind study assessed the effects of empagliflozin on the QT interval. Thirty healthy subjects (14/16 female/male; mean [range] age 34.5 [18–52] years) received single doses of 25 mg (within therapeutic range) and 200 mg (supratherapeutic) empagliflozin and 400 mg moxifloxacin as positive ...

ea0022p292 | Diabetes | ECE2010

Linagliptin, a potent and selective DPP-4 inhibitor, does not prolong the QT interval when given in therapeutic and 20-fold supratherapeutic doses

Ring Arne , Graefe-Mody Ulrike , Port Andreas , Revollo Ivette , Walter Beate , Woerle Hans-Juergen , Iovino Mario , Dugi Klaus

Background: Cardiovascular safety is important for antidiabetic agents. This study followed the ICH E14 guideline to examine the effect of the oral dipeptidyl peptidase-4 (DPP-4) inhibitor linagliptin on the cardiac QT interval in healthy volunteers.Methods: This thorough QT study of linagliptin was performed in healthy subjects, using 5 mg (therapeutic dose) and 100 mg. The randomised, single-dose, placebo-controlled, double-blind, four-way crossover st...

ea0014p445 | (1) | ECE2007

Secondary adrenal failure and secondary amenorrhea due to hydromorphone treatment

Müssig Karsten , Knaus-Dittmann Daniele , Schmidt Helmut , Mörike Klaus , Häring Hans-Ulrich

Objective: Opioids are among the most commonly used symptomatic treatments of somatoform pain disorder. Human and animal studies suggest that chronic exposure to opioids suppresses the hypothalamo-pituitary-adrenal (HPA) and the hypothalamic-pituitary-gonadal axis. We report on a rare case of secondary adrenal failure and secondary amenorrhea due to hydromorphone treatment.Case report: A 32-year-old female patient presented with fatigue, weakness, orthos...

ea0011p51 | Clinical case reports | ECE2006

Isolated ACTH deficiency following long-term benzodiazepine treatment

Müssig K , Friess E , Mörike K , Häring H-U , Overkamp D

Objective: Benzodiazepines are among the most commonly used symptomatic treatment of insomnia and anxiety. Human and animal studies suggest that benzodiazepines suppress the hypothalamo-pituitary adrenal (HPA) axis. We report on a rare case of isolated ACTH deficiency due to long-term treatment with flunitrazepam.Case report: A 66-year-old man presented to our outpatient department with persistent feelings of physical exhaustion, low vitality, reduced da...

ea0014p446 | (1) | ECE2007

Pseudophaeochromocytoma in Parkinson’s disease

Müssig Karsten , Pfäfflin Albrecht , Knaus-Dittmann Daniele , Horger Marius , Mörike Klaus , Häring Hans-Ulrich , Schleicher Erwin D

Objective: Despite combination with peripheral decarboxylase inhibitors significant amounts of L-dopa are peripherally metabolised. In patients with Parkinson’s disease (PD) treated with L-dopa and a dopa decarboxylase inhibitor, urinary dopamine concentrations are markedly elevated. We describe here a L-dopa treated PD patient presenting with a clinical and biochemical picture suspicious of phaeochromocytoma.Case report: A 73-year-old female patien...

ea0011p52 | Clinical case reports | ECE2006

Infertility and bilateral testicular masses due to 21-hydroxylase deficiency

Müssig K , Kaltenbach S , Maser-Gluth C , Hartmann MF , Wudy SA , Horger M , Gallwitz B , Raue F , Häring H-U , Schulze E

Objective: Congenital adrenal hyperplasia results from 21-hydroxylase deficiency in more than ninety percent of cases. The classical form of 21-hydroxylase deficiency presents in the neonatal period with virilization or adrenal insufficiency, with or without concurrent salt wasting. We report on a rare case of classic 21-hydroxylase deficiency diagnosed in late adulthood.Case report: A 39-year-old male patient presented for workup of infertility. Urologi...